Abji F, Lee K, Math M, et al. - Given that serum levels of C-X-C motif chemokine 10 (CXCL10) reduced after PsA onset, researchers estimated CXCL10 levels over time in psoriasis individuals who developed PsA to ascertain if the drop in CXCL10 was specific to these people and further evaluate its relationship with PsA development. Rheumatologists measured the involvement of PsA annually in prospectively followed patients with no arthritis (psoriasis cutaneous [PsC]). Based on psoriasis duration and the interval between follow-up visits, PsC patients who developed PsA (converters) were matched to those that did not develop PsA (non-converters). A significant difference was found in the trend of CXCL10 levels between converters (n = 24) and non-converters (n = 16) pre-conversion/pseudo-conversion. A large difference in CXCL10 has been identified in PsC patients that are destined to develop PsA over time. According to this exploratory analysis, the relationship of CXCL10 with PsA development in PsC patients was supported and justifies the further study of the predictive ability of this chemokine.